SCIRP Mobile Website

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Sinclair, A., Morley, J.E., Rodriguez-Mañas, L., et al. (2012) Diabetes Mellitus in Older People: Position Statement on Behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older eople (EDWPOP), and the International Task Force of Experts in Diabetes. Journal of the American Medical Directors Association, 13, 497-502.
http://dx.doi.org/10.1016/j.jamda.2012.04.012

has been cited by the following article:

  • TITLE: Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments

    AUTHORS: Katsunori Suzuki, Yurie Mistuma, Takaaki Sato, Mariko Hatta

    KEYWORDS: Elderly, Sitagliptin, Type 2 Diabetes Mellitus

    JOURNAL NAME: International Journal of Clinical Medicine, Vol.6 No.9, September 23, 2015

    ABSTRACT: Background: The purpose of this study was to evaluate the effects of sitagliptin in elderly patients with type 2 diabetes aged 75 years or older versus those aged 65 - 74 years. Methods: Outpatients aged 65 years or older with type 2 diabetes who received sitagliptin at a dose of 50 mg daily for 6 months were divided into two groups: those who were 75 years and older and those who were 65 - 74 years. The efficacy and safety were retrospectively evaluated by comparison of laboratory values before and after the administration of sitagliptin and by review of adverse events after treatment. Results: One hundred and twelve older patients with type 2 diabetes were studied. Six months after the initiation of sitagliptin, participants’ hemoglobin A1c was significantly decreased by 1.09% ± 0.8% in 65 - 74-year-olds (66 patients; mean age, 69.1 ± 3.0 years; mean HbA1c before administration, 8.4% ± 0.8%) and by 1.05% ± 0.8% in patients 75 years or older (46 patients; mean age, 79.8 ± 4.1 years; mean HbA1c before administration, 8.5% ± 0.7%). There was no significant difference in hemoglobin A1c between the two groups. Furthermore, sitagliptin was well tolerated in both age groups. Conclusions: In elderly patients (75 years or older) with type 2 diabetes, the effect of sitagliptin was similar that in older patients (younger than 75 years) with type 2 diabetes.